[{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2020","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"","sponsorNew":"Palatin Technologies \/ AMAG","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ AMAG"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palatin Technologies \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Bremelanotide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 22, 2024

                          Lead Product(s) : Bremelanotide Acetate,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with PDE5i for the treatment of erectile dysfunction.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          June 20, 2024

                          Lead Product(s) : Bremelanotide Acetate,Undisclosed

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          June 12, 2024

                          Lead Product(s) : Bremelanotide Acetate,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : PT-141 (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

                          Brand Name : PT-141

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          May 02, 2024

                          Lead Product(s) : Bremelanotide Acetate,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Cosette expands its women's health platform by acquiring Vyleesi (bremelanotide acetate), first as-needed treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : $12.0 million

                          January 03, 2024

                          Lead Product(s) : Bremelanotide Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Cosette Pharma

                          Deal Size : $171.0 million

                          Deal Type : Acquisition

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Cosette expands its women's health platform through divestment by adding Vyleesi, the first approved as-needed treatment for premenopausal women with acquired hypoactive sexual desire disorder.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : $12.0 million

                          January 02, 2024

                          Lead Product(s) : Bremelanotide Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Cosette Pharma

                          Deal Size : $171.0 million

                          Deal Type : Divestment

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorde...

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : $12.0 million

                          December 20, 2023

                          Lead Product(s) : Bremelanotide Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Cosette Pharma

                          Deal Size : $171.0 million

                          Deal Type : Divestment

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 10, 2023

                          Lead Product(s) : Bremelanotide Acetate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 08, 2023

                          Lead Product(s) : Bremelanotide Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Fosun Pharmaceutical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : BMT-701 (bremelanotide) is a synthetic peptide analogue of melanocyte stimulating hormone alpha (MSHα), and its metabolism is by hydrolysis of amide bonds and digestion by cellular peptidases.

                          Brand Name : BMT-701

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          January 19, 2023

                          Lead Product(s) : Bremelanotide Acetate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank